Moderna coronavirus vaccine tremendously encouraging – CDC

0
78

… About 100m Americans have received jabs

A TREMENDOUSLY encouraging real-world study shows the risk of getting infected with coronavirus was cut by 90 per cent after people received two doses of the Pfizer or Moderna vaccine, the CDC said yesterday, as Moderna announced shipment of 100 millionth dose of its vax.

  Disclosing this, the Centers for Disease Control and Prevention Director, Rochelle Walensky said during the White House COVID-19 Response Team briefing yesterday said its study looked at the effectiveness of the Pfizer and Moderna vaccines in preventing infections among nearly 4,000 health care personnel, first responders and other essential workers from December to March.

  According to the CDC, the study found that the risk of infection was reduced by 90 per cent after individuals received the two recommended doses of the vax.

READ MORE:  Pfizer set with test third version vaccine on S' African COVID-19 strain

  The study also found that even after the first shot, the risk of infection decreased by 80 per cent after two weeks while affirming that the findings are consistent with clinical trial data.

  “This study is tremendously encouraging and complements other recent studies published in the New England Journal of Medicine and discussed by Dr. Fauci last week, among similar populations at a high risk of exposure to COVID-19 because of their occupations,”

  “These findings also underscore the importance of getting both of the recommended doses of the vaccine in order to get the greatest level of protection against COVID-19, especially as our concerns about variants escalate,” she added.

  Meanwhile, Cambridge-based Moderna yesterday announced that it shipped the 100 millionth dose of its coronavirus vaccine to the U.S. government.

READ MORE:  Everyone must be vaccinated to defeat pandemic ― FG

  “This is a most heartening milestone,” CEO of Moderna, Stephane Bancel, said as the biotechnology company announced the shipment of its 100 millionth dose.

  “I would like to thank the millions of people who have put their confidence in Moderna’s science and our COVID-19 vaccine,” she said.

Adding, “we are encouraged by the fact that more than 67 million doses have been administered in the U.S. and we are humbled to know that we are helping address this worldwide pandemic with our vaccine.”

  It will be recalled that Moderna, a company pioneering messenger RNA (mRNA) therapeutics and vaccines, developed an mRNA vaccine against COVID-19.

  The drug manufacturing giant received emergency use authorisation from the Food and Drug Administration on December 18. Monthly shipments to the feds in the year’s first quarter were 18 million doses in January, 26 million doses in February and 44 million doses to date in March.

READ MORE:  Oyo begins COVID-19 vaccination

  Looking ahead, the company expects to ship 40 million to 50 million doses per month to the U.S. government to fulfill its commitments of the second 100 million doses by the end of May and the third 100 million doses by the end of July.

  “We are working diligently to ramp up our supplies outside of the U.S. as well,” Bancel said.

  Johnson & Johnson says it has agreed to provide up to 400 million doses of its single-dose COVID-19 vaccine to African countries, starting this summer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here